176 related articles for article (PubMed ID: 32758788)
41. Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ
Newmeyer MN; Swortwood MJ; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
Clin Chem; 2017 Mar; 63(3):647-662. PubMed ID: 28188235
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of ten oral fluid point-of-collection drug-testing devices.
Walsh JM; Crouch DJ; Danaceau JP; Cangianelli L; Liddicoat L; Adkins R
J Anal Toxicol; 2007; 31(1):44-54. PubMed ID: 17389083
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of four oral fluid devices (DDS®, Drugtest 5000®, Drugwipe 5+® and RapidSTAT®) for on-site monitoring drugged driving in comparison with UHPLC-MS/MS analysis.
Strano-Rossi S; Castrignanò E; Anzillotti L; Serpelloni G; Mollica R; Tagliaro F; Pascali JP; di Stefano D; Sgalla R; Chiarotti M
Forensic Sci Int; 2012 Sep; 221(1-3):70-6. PubMed ID: 22554872
[TBL] [Abstract][Full Text] [Related]
44. Drugged Driving in Wisconsin: Oral Fluid Versus Blood.
Edwards LD; Smith KL; Savage T
J Anal Toxicol; 2017 Jul; 41(6):523-529. PubMed ID: 28830121
[TBL] [Abstract][Full Text] [Related]
45. Suitability of SoToxa® Oral Fluid Screening Over Time: Re-Examination of Drugged Driving in Wisconsin.
Savage T; Sanders T; Pieters R; Miles A; Barkholtz H
J Anal Toxicol; 2022 Oct; 46(8):825-834. PubMed ID: 35767245
[TBL] [Abstract][Full Text] [Related]
46. An analytical evaluation of eight on-site oral fluid drug screening devices using laboratory confirmation results from oral fluid.
Blencowe T; Pehrsson A; Lillsunde P; Vimpari K; Houwing S; Smink B; Mathijssen R; Van der Linden T; Legrand SA; Pil K; Verstraete A
Forensic Sci Int; 2011 May; 208(1-3):173-9. PubMed ID: 21183299
[TBL] [Abstract][Full Text] [Related]
47. Roadside drug testing: comparison of two legal approaches in Belgium.
Van der Linden T; Wille SM; Ramírez-Fernandez M; Verstraete AG; Samyn N
Forensic Sci Int; 2015 Apr; 249():148-55. PubMed ID: 25700110
[TBL] [Abstract][Full Text] [Related]
48. An evaluation of on-site oral fluid drug screening devices DrugWipe 5+ and Rapid STAT using oral fluid for confirmation analysis.
Pehrsson A; Blencowe T; Vimpari K; Langel K; Engblom C; Lillsunde P
J Anal Toxicol; 2011 May; 35(4):211-8. PubMed ID: 21513614
[TBL] [Abstract][Full Text] [Related]
49. Field Detection of Drugs of Abuse in Oral Fluid Using the Alere™ DDS®2 Mobile Test System with Confirmation by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).
Krotulski AJ; Mohr ALA; Friscia M; Logan BK
J Anal Toxicol; 2018 Apr; 42(3):170-176. PubMed ID: 29301050
[TBL] [Abstract][Full Text] [Related]
50. Confirmation by LC-MS of drugs in oral fluid obtained from roadside testing.
Concheiro M; de Castro A; Quintela O; Cruz A; López-Rivadulla M
Forensic Sci Int; 2007 Aug; 170(2-3):156-62. PubMed ID: 17658709
[TBL] [Abstract][Full Text] [Related]
51. Long-term stability of cannabinoids in oral fluid after controlled cannabis administration.
Scheidweiler KB; Andersson M; Swortwood MJ; Sempio C; Huestis MA
Drug Test Anal; 2017 Jan; 9(1):143-147. PubMed ID: 27539096
[TBL] [Abstract][Full Text] [Related]
52. Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use.
Gryczynski J; Schwartz RP; Mitchell SG; O'Grady KE; Ondersma SJ
Drug Alcohol Depend; 2014 Aug; 141():44-50. PubMed ID: 24932945
[TBL] [Abstract][Full Text] [Related]
53. Benzodiazepines in the oral fluid of Spanish drivers.
Herrera-Gómez F; García-Mingo M; Álvarez FJ
Subst Abuse Treat Prev Policy; 2020 Feb; 15(1):18. PubMed ID: 32093743
[TBL] [Abstract][Full Text] [Related]
54. Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC-MS-MS.
da Cunha KF; Oliveira KD; Huestis MA; Costa JL
J Anal Toxicol; 2020 Oct; 44(7):697-707. PubMed ID: 32685960
[TBL] [Abstract][Full Text] [Related]
55. Screening for drugs in oral fluid: illicit drug use and drug driving in a sample of Queensland motorists.
Davey J; Leal N; Freeman J
Drug Alcohol Rev; 2007 May; 26(3):301-7. PubMed ID: 17454020
[TBL] [Abstract][Full Text] [Related]
56. Drinking drivers and drug use on weekend nights in the United States.
Voas RB; Lacey JH; Jones K; Scherer M; Compton R
Drug Alcohol Depend; 2013 Jun; 130(1-3):215-21. PubMed ID: 23265090
[TBL] [Abstract][Full Text] [Related]
57. Use of psychoactive substances by goods carriage drivers associated with Kerala, India.
Siva Prasad MS; Priyatha CV; K Joseph J; Aneesh EM
Traffic Inj Prev; 2023; 24(8):663-669. PubMed ID: 37603111
[TBL] [Abstract][Full Text] [Related]
58. Alcohol and illicit drugs in drivers involved in road traffic crashes in Italy. An 8-year retrospective study.
Barone R; Pelletti G; Garagnani M; Giusti A; Marzi M; Rossi F; Roffi R; Fais P; Pelotti S
Forensic Sci Int; 2019 Dec; 305():110004. PubMed ID: 31707239
[TBL] [Abstract][Full Text] [Related]
59. Cozart RapiScan Oral Fluid Drug Testing System: an evaluation of sensitivity, specificity, and efficiency for cocaine detection compared with ELISA and GC-MS following controlled cocaine administration.
Kolbrich EA; Kim I; Barnes AJ; Moolchan ET; Wilson L; Cooper GA; Reid C; Baldwin D; Hand CW; Huestis MA
J Anal Toxicol; 2003 Oct; 27(7):407-11. PubMed ID: 14606993
[TBL] [Abstract][Full Text] [Related]
60. Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results.
Desrosiers NA; Huestis MA
J Anal Toxicol; 2019 Jul; 43(6):415-443. PubMed ID: 31263897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
